Humacyte, Inc.

HUMA · NASDAQ

Company research

Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform company founded in 2004 and headquartered in Durham, North Carolina, focused on developing and manufacturing off-the-shelf, universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems. The company leverages its proprietary scientific technology platform to engineer human acellular vessels (HAVs) — decellularized biological scaffolds designed to integrate with a patient's own tissue without inducing immune rejection or a foreign body response. Humacyte is building a pipeline of HAVs targeting the vascular repair, reconstruction, and replacement market, with key indications including vascular trauma, arteriovenous access for hemodialysis, peripheral arterial disease, coronary artery bypass grafting, and pediatric heart surgery, as well as cellular therapeutic delivery such as pancreatic islet cell transplantation for Type 1 diabetes. Led by CEO Laura E. Niklason and supported by approximately 218 full-time employees, Humacyte trades on the NASDAQ Global Select Market with a current market capitalization of approximately $132 million.

Research reports

Finimize · May 23, 2026Humacyte’s Next Test: Can Its Bioengineered Vessel Find Demand?

This Finimize asset snapshot presents Humacyte as a high‑risk, high‑reward “commercializing biotech”, highlighting FDA‑approved SYMVESS, a pivotal V012 Phase III dialysis trial readout expected around June 11, 2026, and a possible supplemental BLA in H2 2026 as key upside catalysts. It balances these against severe operating losses, heavy dilution and financing needs, Nasdaq minimum‑bid listing risk, and extremely high volatility, concluding that only investors comfortable with binary clinical and funding outcomes should consider exposure until commercial traction and cash‑flow metrics improve.